Drug Type Small molecule drug |
Synonyms FA, FSA |
Target |
Action inhibitors, antagonists |
Mechanism KDM1A inhibitors(Lysine-specific histone demethylase 1 inhibitors), TLR4 antagonists(Toll like receptor 4 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization- |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Non-Small Cell Lung Cancer | Preclinical | China | 28 Oct 2025 | |
| Liver Diseases, Alcoholic | Preclinical | China | 08 May 2025 | |
| Osteoarthritis | Preclinical | China | 01 Dec 2024 | |
| Esophageal Squamous Cell Carcinoma | Preclinical | China | 24 Jul 2024 | |
| Parkinson Disease | Preclinical | China | 01 Mar 2024 |





